Updated Analysis of the POSEIDON Trial in mNSCLC from World Lung 2022

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.